Palbociclib (PD-0332991) HCl

Licensed by Pfizer Catalog No.S1116

Palbociclib (PD-0332991) HCl Chemical Structure

Molecular Weight(MW): 483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 570 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 18 Publications

9 Customer Reviews

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Features Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
Targets
CDK4/CyclinD3 [1]
(Cell-free assay)		 CDK4/CyclinD1 [1]
(Cell-free assay)		 CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
In vitro

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 M3;DWGtqdmG|ZTDBd5NigQ>? M3jzUlI1KGh? NIrYPWNKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= M2ntUVI1PjRzMUCz
COLO205 M4LaUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn1N|FOPzJiaB?= NXjHfXRLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1? MkXzNlQ3PDFzMEO=
U937 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\BN|czKGh? NH63WIVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO NYnYXmtMOjR4NEGxNFM>
MOLM13 NFfJWXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHJTXI4OiCq MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2RTF2xN{Bk\WyuczDoZZJjd3KrbnegSmxVOyCLVFSgcZV1[W62IHHzd4V{e2WmIHHzJIlv[2:{cH;yZZRqd25ib3[gX|NJZXSqeX3p[Ilv\SCrboTvJGRPSSC5aYToJGlEPTBib3[gNE4xQTZizszN MmLhNlQ3PDFzMEO=
MOLM13 NWf6RXZOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV63NkBp MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NIfycpEzPDZ2MUGwNy=>
MDA-MB-435 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWOyOEBp NH;yPIRKSzVyPUCuNVYh|ryP M1vX[VE2QDBzOEOx
K562 MVnDfZRwfG:6aXOgRZN{[Xl? M4r3Nlk3KGh? NHHGbGlFVVOR M1;KW2lEPTB;MjFOwG0> M2jZVlI1PDF5NU[2
DU145 M17JfWN6fG:2b4jpZ{BCe3OjeR?= MlToPVYhcA>? M{Dy[mROW09? M2Hid2lEPTB;Nz61JO69VQ>? MW[yOFQyPzV4Nh?=
MDA-MB-231 NXLzZ3NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTPNUDPxE1? MVWyOEBp NHnK[oFFVVOR MWPD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgS|EheGijc3W= M2fyPVI1PDF5NU[2
MCF7 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfReYEyKM7:TR?= NY[0OmNQOjRiaB?= NV[5eYhKTE2VTx?= NGHFUIhE\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> M3LCe|I1PDF5NU[2
MCF7 M2XpXmtqdmG|ZTDBd5NigQ>? NWrWOZNDPSEQvF2= NHz1bHYzPCCq MkfXSG1UVw>? NWTtdZhlUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBETEt2L3P5Z4xqdkRzIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZicnX0bY5w[myjc4TvcYEheGixc4Doc5J6dGG2aX;uJIF1KFOncke4NC=> NIfPUpozPDRzN{W2Oi=>
MDA-MB-231 NWS5R21YU2mwYYPlJGF{e2G7 MXm1JO69VQ>? MXWyOEBp MlPPSG1UVw>? M4rBc2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgR2RMPC:leXPsbY5FOSCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKHKndHnuc4Jt[XO2b33hJJBpd3OyaH;yfYxifGmxbjDheEBU\XJ5OEC= MW[yOFQyPzV4Nh?=
MDA-MB-231 NVHpRpBOTnWwY4Tpc44hSXO|YYm= MYCxMVExKM7:TR?= NXy1eINsOjRiaB?= MYnEUXNQ M1nueoRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYOgZZN{\XO|ZXSgZZMhWEGUUDDjcIVifmGpZR?= M1;jeFI1PDF5NU[2
MCF7 Mni4SpVv[3Srb36gRZN{[Xl? NF75dYkyNTFyIN88US=> NYPWOGJSOjRiaB?= MnTWSG1UVw>? NHzVVJdld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= M{PyeFI1PDF5NU[2
MDA-MB-231 NYPoRmlTTnWwY4Tpc44hSXO|YYm= M3HrTVAvPS1zIN88US=> MXO0PEBp NUL4N|NHTE2VTx?= MlribIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> MVuyOFQyPzV4Nh?=
MCF7 M{TMZmZ2dmO2aX;uJGF{e2G7 Ml3jNE42NTFizszN NX3qdWR{PDhiaB?= M2DOUWROW09? M3rOUohieyCwbzDD[YxtKGO7Y3zlJIFzemW|dDDhd5Nme3OnZDDhd{Bi[2O3bYXsZZRqd25iYYSgd5VjNUdzIIDoZZNm MXeyOFQyPzV4Nh?=
697 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzQOotKSzVyPUG0PE4{QCCwTR?= MoLBV2FPT0WU
P12-ICHIKAWA NGPJO5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;HOJhvUUN3ME25Ok4xPCCwTR?= M3;TXHNCVkeHUh?=
NB69 M{Xx[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2DJdmlEPTB;MU[xMlghdk1? M1\KXnNCVkeHUh?=
EoL-1 NWnS[W1NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrkTWM2OD1zOEeuNlYhdk1? NHvPW3dUSU6JRWK=
BHT-101 MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUHJXHlWUUN3ME2xPVgvOjVibl2= MoK3V2FPT0WU
SK-NEP-1 NUmzeopoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHVTWM2OD1{MkCuNFIhdk1? M1e4c3NCVkeHUh?=
MHH-NB-11 NHiwN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfMWll[UUN3ME2yNlAvOTlibl2= NIHufJhUSU6JRWK=
AsPC-1 Mn75S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fTZmlEPTB;MkWyMlU{KG6P M4nmSHNCVkeHUh?=
ES1 NILoeW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ3Nj6yOUBvVQ>? MnPZV2FPT0WU
LAMA-84 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrPTWM2OD1{NUiuNVkhdk1? MUjTRW5ITVJ?
MOLT-16 NUL1XmdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4X5[GlEPTB;MkW4MlQ6KG6P NYrTPIVKW0GQR1XS
ES7 NXW4[oJkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPpc41KSzVyPUK3N{4xQSCwTR?= M2HyVHNCVkeHUh?=
KY821 NXHHdFI5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DJZmlEPTB;M{G0MlEhdk1? MoOwV2FPT0WU
RT-112 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HEUGlEPTB;M{KxMlA2KG6P MoPxV2FPT0WU
HL-60 NH:zboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTN2MD62OkBvVQ>? NHvFeVVUSU6JRWK=
MOLT-4 NYPVUGFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDu[IZGUUN3ME2zOFUvOTNibl2= MXXTRW5ITVJ?
KARPAS-45 Mkf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\HTWM2OD1|N{[uNVYhdk1? MYnTRW5ITVJ?
SK-N-AS MlnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN6Nz64N{BvVQ>? NFLmSo1USU6JRWK=
CTB-1 NWDPd44xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;lbIVLUUN3ME20NFUvODJibl2= MkHXV2FPT0WU
NKM-1 M2PkNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXOTWM2OD12MUGuPFkhdk1? MVLTRW5ITVJ?
HTC-C3 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTR|Mj65OUBvVQ>? MWTTRW5ITVJ?
BE-13 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTR2ND6yO{BvVQ>? M32wVXNCVkeHUh?=
KOSC-2 M1P3eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTR4Nj65JI5O NH;ZNIFUSU6JRWK=
NB14 NHnocY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDjTWM2OD12OEOuOVghdk1? M2TaUXNCVkeHUh?=
CAL-27 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrEXHBKSzVyPUS5OE42QSCwTR?= MlnaV2FPT0WU
H9 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknFTWM2OD12OUWuOFMhdk1? NXr2fIhkW0GQR1XS
RS4-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDWdYlLUUN3ME21NFQvPzNibl2= NHjhdZNUSU6JRWK=
PA-1 NV\TeVkzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXoOIVKSzVyPUWwPU45PiCwTR?= M{Dq[nNCVkeHUh?=
MV-4-11 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7VcpRKSzVyPUWxN{45PSCwTR?= MV\TRW5ITVJ?
OS-RC-2 NFTscm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3OGlEPTB;NUKxMlYzKG6P MVPTRW5ITVJ?
RPMI-8226 NEjTRm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{e2c2lEPTB;NUK2Mlg3KG6P NWn0O4JJW0GQR1XS
HGC-27 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkm4TWM2OD13NkSuPVkhdk1? MnjKV2FPT0WU
CHP-212 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkDzTWM2OD13OUOuOVkhdk1? MVTTRW5ITVJ?
NB10 NUHTemxpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{T5ZmlEPTB;NUm5MlE5KG6P M3fJbXNCVkeHUh?=
HH M{LNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3RTWM2OD13OUmuOFMhdk1? NGrzO3lUSU6JRWK=
EW-16 NV63UpJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUT5[3FxUUN3ME22NFMvPTJibl2= NVTrRXVlW0GQR1XS
ES8 MojzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{X5UGlEPTB;NkC1MlIyKG6P NHTkSHVUSU6JRWK=
HAL-01 NGnNeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTZyNT62O{BvVQ>? M1XVV3NCVkeHUh?=
A204 NYrsfmg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PvUGlEPTB;NkOzMlkyKG6P NUXvW4JFW0GQR1XS
MHH-PREB-1 M4q2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zBOmlEPTB;NkO2Mlk6KG6P M{\lPHNCVkeHUh?=
EM-2 NF3jeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVjBOFAyUUN3ME22OVAvPjRibl2= MVrTRW5ITVJ?
BV-173 NEK2b3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIX2cVRKSzVyPU[1Nk41QCCwTR?= NUPMUlN2W0GQR1XS
ONS-76 NVfsOYR3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTZ5Nz64NkBvVQ>? MkDHV2FPT0WU
KM-H2 NIfVZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M171cmlEPTB;Nkm1MlU1KG6P M{T0Z3NCVkeHUh?=
D-263MG NUDiZ|NRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVv0TIZvUUN3ME23NVcvOTJibl2= MmKyV2FPT0WU
ES3 M2HSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTd{OD65N{BvVQ>? Mkn3V2FPT0WU
VA-ES-BJ NXu1eWhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIX5U3BKSzVyPUezNk4zPyCwTR?= Mny1V2FPT0WU
NBsusSR MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Hn[GlEPTB;N{SyMlk6KG6P NFPQ[G5USU6JRWK=
NCI-H520 NVvnWm9yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlKyTWM2OD15NE[uOVIhdk1? MWLTRW5ITVJ?
ES5 NEfuSWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{n1d2lEPTB;N{WyMlghdk1? MlvUV2FPT0WU
T-24 NYHTdXh[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DldmlEPTB;N{e4MlcyKG6P MlLIV2FPT0WU
SW962 NFu1V|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRThyOD62N{BvVQ>? NUjRZ3VFW0GQR1XS
EW-3 MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRThyOD63OkBvVQ>? MXLTRW5ITVJ?
RXF393 MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRThzMj63PUBvVQ>? MYrTRW5ITVJ?
U251 MmD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIe3VmlKSzVyPUixN{45QCCwTR?= M{TlZ3NCVkeHUh?=
CAMA-1 MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPpcpdXUUN3ME24N|MvQTRibl2= Mme0V2FPT0WU
JVM-3 MknYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPQTWM2OD16NUGuO|ghdk1? MV\TRW5ITVJ?
COLO-800 NWn2WXNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4Tke2lEPTB;OEm3Mlc5KG6P M3;GNHNCVkeHUh?=
OVCAR-5 NXmxSFNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTlyMD6xJI5O NX\GOIxVW0GQR1XS
LB1047-RCC MlvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfzTWM2OD17MkeuOVYhdk1? NInlSJVUSU6JRWK=
SW954 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTl{OT60NUBvVQ>? MkDTV2FPT0WU
J-RT3-T3-5 NEPBUllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2GwPWlEPTB;OUO2MlA3KG6P MknWV2FPT0WU
Mewo M{nLbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PTbWlEPTB;OUO2MlYhdk1? MXjTRW5ITVJ?
NCI-H1770 NGrVeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;X[WlEPTB;OUSwMlU2KG6P NXXJS3F5W0GQR1XS
HO-1-N-1 M4H3c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGrQdFZKSzVyPUm2Nk45OSCwTR?= NEPjOVJUSU6JRWK=
HSC-3 MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3n1V2lEPTB;OU[2MlQ5KG6P M1zQc3NCVkeHUh?=
TYK-nu MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYWzR5FYUUN3ME25PVgvOjVibl2= M1\yVXNCVkeHUh?=
KYSE-150 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XaemlEPTB;MT6wNFA4PiEQvF2= NGL4TohUSU6JRWK=
SN12C NIr0S|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1jqWGlEPTB;MT6wNFg4PSEQvF2= MXTTRW5ITVJ?
MOLT-13 MlrXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTFwMEG0NlEh|ryP MonpV2FPT0WU
TE-11 Mn\5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTFwMES4NVIh|ryP NEjvb4pUSU6JRWK=
DB NFrnWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTFwMEeyO|Mh|ryP M3n6eXNCVkeHUh?=
CAL-39 Ml;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PFXGlEPTB;MT6wO|UzOiEQvF2= NVrmXopOW0GQR1XS
A3-KAW NVXoZ|hLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHFTlJiUUN3ME2xMlA5PDB6IN88US=> M4DYN3NCVkeHUh?=
CHP-134 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXuwelJPUUN3ME2xMlEyQDB5IN88US=> NYTnbYVDW0GQR1XS
TGW NI\XPW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn7BTWM2OD1zLkGyN|k2KM7:TR?= M2jTWnNCVkeHUh?=
QIMR-WIL M2nZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPqTWM2OD1zLkGzNVM1KM7:TR?= M4f0dHNCVkeHUh?=
NCI-SNU-1 NIXVfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXrTWM2OD1zLkG2N|U1KM7:TR?= NVGwenlOW0GQR1XS
CGTH-W-1 NHjxNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHNTWM2OD1zLkG3NVg3KM7:TR?= NXvp[mgyW0GQR1XS
MHH-ES-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3z3NGlEPTB;MT6xO|k5PiEQvF2= NWfQdGhmW0GQR1XS
LB2241-RCC M3\5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlq5TWM2OD1zLkG4OlIh|ryP NGHORYhUSU6JRWK=
ML-2 NUHUOYhoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzSTWM2OD1zLkKwO|M1KM7:TR?= MnnIV2FPT0WU
COR-L23 NEO0VlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHXfoNwUUN3ME2xMlIzQTN|IN88US=> MoTRV2FPT0WU
BFTC-905 NGLi[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEjWNJlKSzVyPUGuNlQzPjdizszN MVLTRW5ITVJ?
Hs-578-T NFeyc3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MULJR|UxRTFwMkW4NVch|ryP M2DSW3NCVkeHUh?=
KG-1 MkHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXxWVdrUUN3ME2xMlI3Pjh4IN88US=> NVHuZ3M4W0GQR1XS
HEL M1:wUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwMkmzN|gh|ryP MnezV2FPT0WU
A549 NYG0XYNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHhTWM2OD1zLkK5N|k6KM7:TR?= NWm4RnBVW0GQR1XS
COLO-741 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{X6eWlEPTB;MT6zNlA5QSEQvF2= MUjTRW5ITVJ?
PC-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTjdlJPUUN3ME2xMlM2OjJzIN88US=> MkXxV2FPT0WU
HOS NUfVSZBVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTFwM{WyPVYh|ryP M1PjdXNCVkeHUh?=
HT-1080 NXW1eoJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\zcWlEPTB;MT6zO|UyQSEQvF2= NV3sdWk2W0GQR1XS
TE-8 NGTIbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPVbId4UUN3ME2xMlQyPzd2IN88US=> M1vMPXNCVkeHUh?=
BHY Mn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfVTWM2OD1zLkS2PVI{KM7:TR?= MonZV2FPT0WU
BB65-RCC NIrxWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\lTWM2OD1zLkWwOVI5KM7:TR?= MVzTRW5ITVJ?
HN MlPjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFH0T5ZKSzVyPUGuOVQxPzFizszN Mnq3V2FPT0WU
NCI-H441 M4LifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPrOFU1UUN3ME2xMlU1QTB5IN88US=> MmLRV2FPT0WU
RPMI-8866 NX:2[nhxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDiSVlKSzVyPUGuOVg2ODdizszN NGfYUINUSU6JRWK=
CAL-62 NEGyR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1qzWGlEPTB;MT62NFg3OiEQvF2= MnPnV2FPT0WU
MG-63 M{H2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHm2VGlKSzVyPUGuOlE5OTNizszN M4L6SXNCVkeHUh?=
SK-LU-1 M3HRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnDTWM2OD1zLk[yNVUzKM7:TR?= NHiwbZZUSU6JRWK=
BCPAP M4DvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHLcWdXUUN3ME2xMlY3PDV5IN88US=> MXzTRW5ITVJ?
22RV1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwNke4OFMh|ryP MX;TRW5ITVJ?
T47D M4D5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkCxTWM2OD1zLk[4NFYyKM7:TR?= MVLTRW5ITVJ?
MSTO-211H MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LYcGlEPTB;MT62PVYxOyEQvF2= NHW2eldUSU6JRWK=
DEL MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfXR|VKSzVyPUGuO|AzPzNizszN NWS1VVd5W0GQR1XS
H4 Mmi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTFwN{OyNVIh|ryP NXnCZ|VtW0GQR1XS
CAL-51 MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTPbnFKSzVyPUGuO|Q5PTVizszN NFXROJFUSU6JRWK=
ABC-1 Mn\lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmP4TWM2OD1zLke4OVgzKM7:TR?= NUHkUnZxW0GQR1XS
MZ2-MEL MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfNXm1KSzVyPUGuO|k2PDJizszN NX6yfJJIW0GQR1XS
YKG-1 M{j0XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTFwOEGwOlEh|ryP MlraV2FPT0WU
KM12 NHTtfZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHWSXVKSzVyPUGuPFE3ODJizszN NEmzZ3FUSU6JRWK=
L-363 M1nUNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTFwOEe0NVIh|ryP MnzUV2FPT0WU
KU812 MnjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Ze|JKSzVyPUGuPFkzQDJizszN MXrTRW5ITVJ?
LOXIMVI MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4f5TGlEPTB;MT65NVIzQCEQvF2= MVTTRW5ITVJ?
G-401 M4S3e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fNTmlEPTB;MT65NlQzQCEQvF2= NIPW[XJUSU6JRWK=
SW780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PuZ2lEPTB;MT65OlI1PiEQvF2= M1zmUXNCVkeHUh?=
SW872 MlflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHfiUXhKSzVyPUGuPVg{OyEQvF2= MYnTRW5ITVJ?
NB7 M4roN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfDeHJKSzVyPUGuPVk{OjNizszN MX7TRW5ITVJ?
T98G MlvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\5TWM2OD1{LkCwOlY3KM7:TR?= NHH4[JlUSU6JRWK=
SW1710 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3q3OGlEPTB;Mj6wOlk1PSEQvF2= MYjTRW5ITVJ?
NCI-H1573 NVfGdnh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTJwMEeyPVgh|ryP MWHTRW5ITVJ?
KE-37 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTJwMEi5OVEh|ryP MoTYV2FPT0WU
786-0 NITFfIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTJwMUW0N|kh|ryP MYPTRW5ITVJ?
SAS MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17wN2lEPTB;Mj6yNFM4PCEQvF2= NIDVNVVUSU6JRWK=
CAL-54 NUTrWHlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXE[npKSzVyPUKuNlA1OTNizszN NX3lOHBRW0GQR1XS
SF268 NFzIcVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rIc2lEPTB;Mj6yN|EzOiEQvF2= NXfSNYpFW0GQR1XS
SW620 NYHZPZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qxbmlEPTB;Mj6yOlE3QSEQvF2= MXPTRW5ITVJ?
MN-60 NXrtWZhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTJwM{GwOkDPxE1? M2HGenNCVkeHUh?=
EFO-27 MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\SWm9iUUN3ME2yMlMzODV6IN88US=> NVXufJpqW0GQR1XS
NCI-H747 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DtN2lEPTB;Mj6zNlE6QSEQvF2= MXHTRW5ITVJ?
HCC2218 NWPRToFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfKb2xIUUN3ME2yMlM2Ozd2IN88US=> NWXpNlhDW0GQR1XS
MIA-PaCa-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDp[plKSzVyPUKuN|Y1OzdizszN M1\KTnNCVkeHUh?=
SJSA-1 NEO4OW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwM{e3PVYh|ryP MWHTRW5ITVJ?
RKO M1jjZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTJwM{i0PVYh|ryP M37SUXNCVkeHUh?=
NB6 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXiwT4FSUUN3ME2yMlQxOzd2IN88US=> Ml3yV2FPT0WU
ES4 M3nZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDXdIFKSzVyPUKuOFU1OjJizszN NX\HTHgxW0GQR1XS
EGI-1 NHnNdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJwNE[4PFMh|ryP MonpV2FPT0WU
CTV-1 NX7GTFdWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLiTHpKSzVyPUKuOVI4PzNizszN NXfuS5dLW0GQR1XS
NCI-H1355 M2nmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDu[JRpUUN3ME2yMlU2QTVzIN88US=> M4fadXNCVkeHUh?=
GT3TKB NWrsWWdnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vicGlEPTB;Mj61PVE6QSEQvF2= NXvGOHFNW0GQR1XS
SK-HEP-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PrUmlEPTB;Mj61PVI3PiEQvF2= MnTGV2FPT0WU
GAMG MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHLTWM2OD1{LkW5N|k1KM7:TR?= MnPIV2FPT0WU
SK-MES-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJwNkG4NFMh|ryP M17IS3NCVkeHUh?=
RO82-W-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnq2TWM2OD1{Lk[yNFU4KM7:TR?= NVXISFZqW0GQR1XS
ECC10 MoH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr6UYtYUUN3ME2yMlcxOjB4IN88US=> Mo\DV2FPT0WU
MCF7 NHj3SnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwN{G0OlQh|ryP Mn;OV2FPT0WU
D-283MED MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFHrXlFKSzVyPUKuO|I1OyEQvF2= MUHTRW5ITVJ?
RPMI-7951 MkHNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJwN{W2PVQh|ryP MWfTRW5ITVJ?
Ramos-2G6-4C10 MlfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTJwN{ewPVkh|ryP M3jWN3NCVkeHUh?=
KGN Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{Oy[mlEPTB;Mj64NVg5PCEQvF2= MVvTRW5ITVJ?
NUGC-3 NXK4XWNDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2X4b2lEPTB;Mj64NlUxPSEQvF2= MUjTRW5ITVJ?
NCI-H292 MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUTJR|UxRTJwOEWwOVMh|ryP MX3TRW5ITVJ?
Becker M3yyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HmRmlEPTB;Mj65OVg{OiEQvF2= MWLTRW5ITVJ?
NCI-H1299 MmSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTmTWM2OD1|LkC1NlY{KM7:TR?= NXnkbo4{W0GQR1XS
ETK-1 NVvMdWtTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTNwMEW0N{DPxE1? MYPTRW5ITVJ?
TK10 NIrPdVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnYS3VKSzVyPUOuNlAyPjVizszN NWf2VoU3W0GQR1XS
VMRC-RCZ NH\pXZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\KPJU6UUN3ME2zMlM3PDh6IN88US=> NH\jbHdUSU6JRWK=
YH-13 MnLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTNwNESwO|kh|ryP MWHTRW5ITVJ?
DU-145 M3HTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX63PIVjUUN3ME2zMlQ3OjZ7IN88US=> NFe1XHNUSU6JRWK=
SW1088 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fGRWlEPTB;Mz60O|Q4KM7:TR?= MUDTRW5ITVJ?
HOP-92 M3L1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHqTWM2OD1|LkWwN|QzKM7:TR?= M{DaZnNCVkeHUh?=
KP-N-YS NXrE[XVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUDJR|UxRTNwNkKxN|kh|ryP MXvTRW5ITVJ?
NCI-H460 NGXPTZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWroOZE2UUN3ME2zMlY3PzNizszN NGTrUGhUSU6JRWK=
U-2-OS NELLUZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G5d2lEPTB;Mz63NlU{PSEQvF2= MoGwV2FPT0WU
A101D M2iyNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\wUoxOUUN3ME2zMlc3QTN4IN88US=> MWTTRW5ITVJ?
MDA-MB-231 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnqTWM2OD1|LkixPVUyKM7:TR?= NV25dJdUW0GQR1XS
IST-MES1 NV75fJdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjPTHBKSzVyPUOuPFMzKM7:TR?= MlTQV2FPT0WU
COR-L105 NUPG[2h2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NET6e21KSzVyPUSuNFE5KM7:TR?= NVHnbW9tW0GQR1XS
NCI-H1437 MnviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPoeZpIUUN3ME20MlAzOzB{IN88US=> NWLURmZ5W0GQR1XS
CAL-85-1 MmDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\jTWM2OD12LkCyOFYyKM7:TR?= MVTTRW5ITVJ?
MZ1-PC NGD3epNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGSyUllKSzVyPUSuNVg2PTZizszN M3izRnNCVkeHUh?=
VM-CUB-1 MkDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmT1TWM2OD12LkOxNlg1KM7:TR?= MX3TRW5ITVJ?
CHL-1 MnvRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjRfo9lUUN3ME20MlMzOTZ7IN88US=> MmjoV2FPT0WU
MDA-MB-361 NV\jeG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTRwM{OxOVMh|ryP MUjTRW5ITVJ?
NCI-H661 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPVZ2M4UUN3ME20MlUxODl{IN88US=> MXfTRW5ITVJ?
EW-11 M4f5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPLVnhKSzVyPUSuOVIzOzFizszN NX2xUW97W0GQR1XS
BEN NHXGWJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2nMUmlEPTB;ND61NlgyPSEQvF2= NYTER3pkW0GQR1XS
BFTC-909 NIjm[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTRwNU[yO|Uh|ryP NYDjd|lCW0GQR1XS
NCI-H2087 NFHKPWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nkRWlEPTB;ND61PFE3PCEQvF2= M{DGV3NCVkeHUh?=
RVH-421 NEL1Z3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\BTWM2OD12Lk[2Olkh|ryP MWLTRW5ITVJ?
P30-OHK M{LFbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTRwNkiwNFgh|ryP Mm\mV2FPT0WU
NCI-H28 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUPM[oxbUUN3ME20MlgyPjZzIN88US=> NVfnfGtVW0GQR1XS
ES6 NXP3RVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnOzTWM2OD12LkizNFE3KM7:TR?= MVjTRW5ITVJ?
769-P M{TzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTRwOEW5NlYh|ryP NWDBWm43W0GQR1XS
OE33 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnhdoJKSzVyPUSuPFgyPjFizszN MUPTRW5ITVJ?
SW982 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGPHWJBKSzVyPUSuPVUxPjFizszN NWTFfZoyW0GQR1XS
A388 MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTVwMEK5PFMh|ryP NXXmZohxW0GQR1XS
TI-73 NUHj[JpvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnqOI9qUUN3ME21MlA3OTl2IN88US=> Ml22V2FPT0WU
HCT-116 NUjDXFF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4qxc2lEPTB;NT6wPVg5QSEQvF2= MnfYV2FPT0WU
HuP-T3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXqTWM2OD13LkG4O|A6KM7:TR?= NXLwe5VDW0GQR1XS
G-402 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFztVIdKSzVyPUWuNVk1OTZizszN MmLZV2FPT0WU
NCI-H1792 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIroZXFKSzVyPUWuNlQ3OjJizszN NH;oUlRUSU6JRWK=
NCI-H209 NVrqbmw2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIryXoVKSzVyPUWuNlU6PDJizszN MXXTRW5ITVJ?
NCI-H1650 NFLGOnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7hTWM2OD13LkOwOlM1KM7:TR?= NIG5emRUSU6JRWK=
LCLC-97TM1 MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33JbWlEPTB;NT6zNVgxQCEQvF2= MVHTRW5ITVJ?
S-117 NUHVbpVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPPTWM2OD13LkO2PVc3KM7:TR?= NXXZV2Y4W0GQR1XS
GI-ME-N M4mwUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE\yN5FKSzVyPUWuN|k3QDFizszN M1\3V3NCVkeHUh?=
NCI-H2122 NXv1dYR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTVwNEmzPVch|ryP MljKV2FPT0WU
NCI-H1793 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13CO2lEPTB;NT62O|U6OyEQvF2= MV7TRW5ITVJ?
C2BBe1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHjTWM2OD13LkewNFg5KM7:TR?= NULUZoZkW0GQR1XS
TE-12 NXjobVN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjPXpJnUUN3ME21MlgxPTV4IN88US=> NUnJeW5jW0GQR1XS
LCLC-103H M161Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3KU4VKSzVyPUWuPVE4KM7:TR?= MmDDV2FPT0WU
A673 NFXj[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTVwOUG5N|Ih|ryP NVPPSZY3W0GQR1XS
BB30-HNC M4TDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnXW5FKSzVyPUWuPVg{PiEQvF2= NFTQNI5USU6JRWK=
SF295 M4nhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TyS2lEPTB;Nj6wNFQzOiEQvF2= Mnv0V2FPT0WU
KU-19-19 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTEOIt4UUN3ME22MlAyPzNzIN88US=> NV\YZZdrW0GQR1XS
CFPAC-1 M1WzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTZwMES0OFMh|ryP MWfTRW5ITVJ?
LoVo MlP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXjXpFKSzVyPU[uNFUxPjNizszN M3jFOXNCVkeHUh?=
8505C M17oSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXW4[|JsUUN3ME22MlA4PTd|IN88US=> M1nEc3NCVkeHUh?=
GMS-10 NIfWbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\ZTWM2OD14LkG1NFAzKM7:TR?= MnT2V2FPT0WU
Ca9-22 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTZwMU[3NUDPxE1? NU\xdFhRW0GQR1XS
DOK M1n4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4KyN2lEPTB;Nj6yNlA4OiEQvF2= MkLQV2FPT0WU
FADU MkjiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LvcmlEPTB;Nj6yOlA{QSEQvF2= NVHZcVZJW0GQR1XS
BxPC-3 MkSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFW4UWRKSzVyPU[uNlc{OiEQvF2= M1uwWXNCVkeHUh?=
CAL-33 MnzwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTZwMkmyNFEh|ryP NITSTHhUSU6JRWK=
SHP-77 M3TJZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEPSOIZKSzVyPU[uN|E2OTJizszN MlW5V2FPT0WU
LXF-289 MnrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZwM{O0OVUh|ryP M2PpcnNCVkeHUh?=
GB-1 NUHrdYVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXsSlNKSzVyPU[uN|gzKM7:TR?= NFzBb5pUSU6JRWK=
KS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfmR|NKSzVyPU[uN|g1PDdizszN NYiySolIW0GQR1XS
D-502MG NInuXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXqTWM2OD14LkSyN|c3KM7:TR?= NVT2W|R3W0GQR1XS
LAN-6 NWHkfmZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTZwNUGwNlMh|ryP NHnmWYhUSU6JRWK=
H-EMC-SS NXvoeZJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjhVplKSzVyPU[uOVYyPDdizszN MU\TRW5ITVJ?
LC-2-ad M13MWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTZTWM2OD14Lk[wNFc3KM7:TR?= MoHPV2FPT0WU
NCI-H1693 M3HDemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzhTWM2OD14Lk[yNlE2KM7:TR?= MXvTRW5ITVJ?
SK-N-FI MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;vNGlEPTB;Nj63OVA1PCEQvF2= NV20fFZIW0GQR1XS
D-423MG NUTKdoZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfEVJFKSzVyPU[uO|YyOTdizszN MWrTRW5ITVJ?
KNS-42 NIjE[5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXT4doVZUUN3ME22Mlc5OTl5IN88US=> NHjZb|ZUSU6JRWK=
GCT M1exR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTZwOUO4JO69VQ>? MWXTRW5ITVJ?
DSH1 MkCzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\SdoJKSzVyPUeuNFY{OyEQvF2= NVS2ZYxrW0GQR1XS
D-247MG MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTdwMEe4PFEh|ryP M1vtT3NCVkeHUh?=
NCI-SNU-5 MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3sTWM2OD15LkG4N|cyKM7:TR?= MWDTRW5ITVJ?
TE-6 M{nFbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGSz[FFKSzVyPUeuNlA3ODFizszN M3[3WnNCVkeHUh?=
NOMO-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVSyXJBpUUN3ME23MlIzOTJ5IN88US=> NFG3SZBUSU6JRWK=
NB17 NUezbVJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PLWmlEPTB;Nz6zNFMxQSEQvF2= NXLlPFNFW0GQR1XS
EW-22 Ml7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrHdGdKSzVyPUeuN|Q{PDhizszN MlX2V2FPT0WU
EW-13 M4m1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTdwM{WxOlIh|ryP NULFW5RGW0GQR1XS
DOHH-2 NHjrSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Pod2lEPTB;Nz60OFAzKM7:TR?= M2H0UXNCVkeHUh?=
TGBC1TKB MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUT1epFnUUN3ME23MlQ6QDl7IN88US=> NE\obWFUSU6JRWK=
GR-ST MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTdwNUK1PVQh|ryP M3\sV3NCVkeHUh?=
KYSE-520 M3i1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;JTWM2OD15LkW1OVE2KM7:TR?= NHLzWWNUSU6JRWK=
CAPAN-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXRTWM2OD15LkW5OVEh|ryP MWXTRW5ITVJ?
HCE-4 NGG3PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1OzZWlEPTB;Nz62NlI4QSEQvF2= MVPTRW5ITVJ?
MLMA M3XudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;UdZJKSzVyPUeuOlI6PTdizszN NHjuVmZUSU6JRWK=
HT-144 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17pNmlEPTB;Nz62OVM3QCEQvF2= M3;xV3NCVkeHUh?=
KYSE-180 M{HPNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XMSWlEPTB;Nz63NVE3QSEQvF2= NUf3ZWxUW0GQR1XS
TE-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTjfGFKSzVyPUeuPVU6PzFizszN M2nXNXNCVkeHUh?=
IGROV-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{W3d2lEPTB;Nz65PFU2OSEQvF2= NG\vb2RUSU6JRWK=
NCI-H1581 NYrPR4NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjkWmdJUUN3ME24MlAyOiEQvF2= MWTTRW5ITVJ?
SW1990 M1LoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4rCWGlEPTB;OD6wOFY2QSEQvF2= NWHQcHI6W0GQR1XS
EFM-19 NWHIUWg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjtT3FGUUN3ME24MlA5PTR3IN88US=> MXHTRW5ITVJ?
OGR-1 NGLwN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHCTWM2OD16LkSzNFI{KM7:TR?= MlHYV2FPT0WU
U-118-MG M1jrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXkU3BKSzVyPUiuOFM1PjNizszN NE\EW3VUSU6JRWK=
SK-OV-3 NFLSV3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1Xvd2lEPTB;OD60Olc3PSEQvF2= NFnmN|RUSU6JRWK=
KNS-62 NETvSFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRThwNUG3OlEh|ryP MlXzV2FPT0WU
GOTO MmjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXXTWM2OD16LkW3OlM2KM7:TR?= M{LL[HNCVkeHUh?=
8305C Mmq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGzbnRKSzVyPUiuO|A1QDRizszN NFrvOY5USU6JRWK=
RPMI-2650 NFfNOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3uRnZ6UUN3ME24MlcyQTV3IN88US=> NVrScIRLW0GQR1XS
NEC8 M3\Wd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXETWM2OD16Lke0N|A4KM7:TR?= NXzqbZRkW0GQR1XS
KYSE-450 NWjVcWxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUn1N4gyUUN3ME24Mlg3PTR6IN88US=> MVnTRW5ITVJ?
RMG-I M4jneGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmroTWM2OD17LkG0NFU5KM7:TR?= M1v5W3NCVkeHUh?=
CAKI-1 NIPzPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPYOoU{UUN3ME25MlMyQTd7IN88US=> M1Tl[3NCVkeHUh?=
KYSE-510 NYLPTYRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTlwM{W3O|gh|ryP M4DXUHNCVkeHUh?=
A4-Fuk MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M323TWlEPTB;OT6zOlcxOSEQvF2= MVXTRW5ITVJ?
AN3-CA MkHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:1cJRKSzVyPUmuOFU1PDRizszN NH3JS4VUSU6JRWK=
SK-N-DZ NH\PdWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFPMSYlKSzVyPUmuO|I5PDlizszN M1LwW3NCVkeHUh?=
HSC-2 MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDwR252UUN3ME25Mlc3PjJ7IN88US=> NE\0e|JUSU6JRWK=
EW-1 NFTpfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTlwN{mzOlkh|ryP MYLTRW5ITVJ?
D-566MG M4P3UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTlwOEO2OlQh|ryP NHKyZ4VUSU6JRWK=
COLO-792 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LPT2lEPTB;OT65PFc1PiEQvF2= MUHTRW5ITVJ?
TE-10 NEXUZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjXXFJKSzVyPUGwMlA{QTZizszN MVLTRW5ITVJ?
NCI-H650 M3\NUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;xXHdKUUN3ME2xNE41Ojh4IN88US=> M1nLUnNCVkeHUh?=
U-266 M{LxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3iZY9tUUN3ME2xNE41PTVizszN NFzuNFRUSU6JRWK=
Detroit562 MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn70TWM2OD1zMT6wOVE2KM7:TR?= M1vZd3NCVkeHUh?=
NH-12 NVX0b5dCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTXTWM2OD1zMT6xOFQ3KM7:TR?= MXfTRW5ITVJ?
CO-314 NHfBS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTFzLkK4OFIh|ryP NIC0bFVUSU6JRWK=
IST-MEL1 M2e4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jFVWlEPTB;MUGuOVMzOyEQvF2= NGXl[Y5USU6JRWK=
KNS-81-FD MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTFzLkW1Nlch|ryP NH;QflVUSU6JRWK=
SW1463 NXu0TZdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTFzLkW5PFkh|ryP MYjTRW5ITVJ?
NCI-H23 NHrPdm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnixTWM2OD1zMT62OVUzKM7:TR?= M3mxfHNCVkeHUh?=
SK-MEL-2 M4exTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4H0NWlEPTB;MUGuO|E6PyEQvF2= NXrFN4hpW0GQR1XS
NB13 NH3Yc2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HKNWlEPTB;MUKuNVQ6PSEQvF2= NGrJZ4lUSU6JRWK=
Daoy NXTlb|dWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPkPVhTUUN3ME2xNk4zQDV4IN88US=> MXvTRW5ITVJ?
NCI-H1623 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fUUWlEPTB;MUKuN|gxOSEQvF2= NF:4cJpUSU6JRWK=
NMC-G1 NGjQbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4TLWGlEPTB;MUKuO|E4KM7:TR?= M1;kbXNCVkeHUh?=
DK-MG Mlq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrrPIFKSzVyPUGyMlk1QDJizszN M4n6[XNCVkeHUh?=
TCCSUP MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\YOpo6UUN3ME2xN{4yOjh2IN88US=> MVTTRW5ITVJ?
SCC-15 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fudGlEPTB;MUOuNlY2OSEQvF2= M123VXNCVkeHUh?=
NOS-1 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzyTWM2OD1zMz6yPFk{KM7:TR?= MYPTRW5ITVJ?
RH-1 NVnYdm8zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWr5VVNmUUN3ME2xN{4{ODN5IN88US=> MX;TRW5ITVJ?
SK-MEL-3 M4Hxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX36[nkzUUN3ME2xN{4{PzJ6IN88US=> M2j2SXNCVkeHUh?=
NB5 M4n1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWTXd|BSUUN3ME2xN{41ODZ5IN88US=> NX\1cmdvW0GQR1XS
SNU-387 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF|LkWwO|Ih|ryP NXrCPHNtW0GQR1XS
CAL-120 M1PwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfCfmJKSzVyPUGzMlY4OThizszN NW\kOpV{W0GQR1XS
Mo-T M3TvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrOVnk3UUN3ME2xN{44ODdizszN MVPTRW5ITVJ?
LNCaP-Clone-FGC MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjtOpJKSzVyPUGzMlc6QTJizszN MX\TRW5ITVJ?
CAN NYr3VpdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3qzcmlEPTB;MUSuNFI5QCEQvF2= NWHlPVBKW0GQR1XS
SK-MEL-30 NV7KOYpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYWwNGNQUUN3ME2xOE4xPjNizszN MYrTRW5ITVJ?
COLO-678 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVvJR|UxRTF2LkC4NlIh|ryP MnXzV2FPT0WU
SCC-9 NHn4NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Pse2lEPTB;MUSuNVAzOSEQvF2= M3HjeXNCVkeHUh?=
KINGS-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonqTWM2OD1zND6xOFAzKM7:TR?= MYPTRW5ITVJ?
SL-513 NWSyRoJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVftd|BTUUN3ME2xOE4yQDdizszN MWXTRW5ITVJ?
HLE NEW5eINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTF2LkO4OVIh|ryP MnriV2FPT0WU
SW1573 MmKwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF2LkS0N|Uh|ryP MkCwV2FPT0WU
KYSE-140 NFLVeZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljvTWM2OD1zND62N|I4KM7:TR?= M3TrUXNCVkeHUh?=
SK-PN-DW MoLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fCR2lEPTB;MUSuPFAxOSEQvF2= NVvzZXZsW0GQR1XS
A253 Mo\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVzucJNCUUN3ME2xOU4xPjJ3IN88US=> MmDXV2FPT0WU
CAL-12T M13ZT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTiUG42UUN3ME2xOU41PjZ{IN88US=> Mm\UV2FPT0WU
COLO-679 NImxNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPjTWM2OD1zNT63Olg{KM7:TR?= MkPFV2FPT0WU
UACC-257 NH3ld4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTCTWM2OD1zNj6xNlAyKM7:TR?= MXzTRW5ITVJ?
U-87-MG MkHuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrKTWM2OD1zNj6zOVI{KM7:TR?= NV7ZdVcxW0GQR1XS
HCC1806 NIO0eItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXRR4VKSzVyPUG2MlcxPzFizszN NYDGelBHW0GQR1XS
NCI-H2170 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnW1TWM2OD1zNz6yOFQ5KM7:TR?= M1G1U3NCVkeHUh?=
AGS MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTF5LkO4NFgh|ryP NEHOeW5USU6JRWK=
MEL-HO NVPCS5k6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nvOGlEPTB;MUeuO|UxOyEQvF2= MWHTRW5ITVJ?
SW48 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;E[pR7UUN3ME2xO{44PzF4IN88US=> MVvTRW5ITVJ?
HuP-T4 M4TIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrzOGF2UUN3ME2xPE4xOjB4IN88US=> MVzTRW5ITVJ?
NCI-H720 M13YdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXzWYJKSzVyPUG4MlE1ODJizszN MV\TRW5ITVJ?
RCC10RGB NFnXXYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTF6LkG2PVch|ryP M1PienNCVkeHUh?=
HD-MY-Z MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TaUWlEPTB;MUiuNlI2PCEQvF2= NXToVHI4W0GQR1XS
A427 NVLpR4lxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTF6LkWwPVQh|ryP M2m5NnNCVkeHUh?=
HCC2998 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TNU2lEPTB;MUiuOlA2OSEQvF2= MY\TRW5ITVJ?
EPLC-272H MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTF7LkC0N|Qh|ryP NXzRVpFtW0GQR1XS
C32 NWrXU3dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;vTWM2OD1zOT6wOFUh|ryP MnrpV2FPT0WU
UMC-11 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTF7LkKxNlMh|ryP M4T2NnNCVkeHUh?=
CaR-1 NWnEcVNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIeydZpKSzVyPUG5MlY5ODRizszN MlXyV2FPT0WU
KYSE-410 MkDuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTITWM2OD1zOT65NVM6KM7:TR?= NFrCcVJUSU6JRWK=
HuCCT1 NGjB[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTjd2RKSzVyPUKwMlYzQTRizszN M3TnUHNCVkeHUh?=
LB996-RCC NYr5NJY4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDNTWM2OD1{MD63NVY5KM7:TR?= MV3TRW5ITVJ?
KYSE-70 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M32xd2lEPTB;MkCuPFA2QSEQvF2= MlzqV2FPT0WU
CAL-72 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIT0XmZKSzVyPUKwMlkyPSEQvF2= NGTn[pJUSU6JRWK=
Capan-2 MmHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjlUIZKSzVyPUKxMlA1OTNizszN NEKyXGRUSU6JRWK=
PANC-08-13 NH71RVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTJzLkK1NVUh|ryP MUHTRW5ITVJ?
SBC-1 NHrKb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTJzLkOwPFEh|ryP NED6bIRUSU6JRWK=
MFM-223 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTJzLkOzOFIh|ryP NU[4Ong2W0GQR1XS
BB49-HNC MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJzLkW3NVYh|ryP MknVV2FPT0WU
SH-4 M4jXR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn2W25KSzVyPUKxMlY3OThizszN MVzTRW5ITVJ?
HuO9 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJzLkm4NlUh|ryP MWDTRW5ITVJ?
AM-38 M4PzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnTETWM2OD1{Mj6wOFg2KM7:TR?= M{jKUHNCVkeHUh?=
A431 M3zLRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTlTWM2OD1{Mz6yNVE6KM7:TR?= MlG4V2FPT0WU
YAPC Mmj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTJ|LkK2OVEh|ryP NWXGU4t5W0GQR1XS
LU-139 NXHrfm93T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;UfoxEUUN3ME2yN{41QDB7IN88US=> MoPwV2FPT0WU
HEC-1 NEG2T3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTJ|LkS5N|ch|ryP MoHRV2FPT0WU
SCC-25 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTJ2LkOwNFYh|ryP NIPlOZJUSU6JRWK=
HT-29 NYiyZXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrLZ5BKSzVyPUK0MlM5OjNizszN M{jKd3NCVkeHUh?=
PC-14 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlyyTWM2OD1{ND62OVcyKM7:TR?= MmjKV2FPT0WU
Calu-6 NWjMUHA5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7NTWM2OD1{NT61NFcyKM7:TR?= MmnqV2FPT0WU
SJRH30 M3qwXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJ3Lk[0PVYh|ryP NInKSJVUSU6JRWK=
ChaGo-K-1 MofIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTJ4LkG2Nlkh|ryP MVjTRW5ITVJ?
IA-LM MmDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTJ4LkO2OFUh|ryP NWT1SnhNW0GQR1XS
GP5d NYrDe5V7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\he3ZEUUN3ME2yOk41PDlzIN88US=> MlTUV2FPT0WU
NCI-H2291 NFz6PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\HfZlKSzVyPUK2MlY2PDFizszN NHnWfYZUSU6JRWK=
BALL-1 NEjsZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXKyN4FQUUN3ME2yOk46Ozl5IN88US=> NULoWJFtW0GQR1XS
HCC1954 NHK4TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PCeGlEPTB;Mk[uPVgxQCEQvF2= NFLuRoVUSU6JRWK=
NCI-H2452 M12ySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\EV5E{UUN3ME2yO{41OTZ|IN88US=> NIT2WXVUSU6JRWK=
LU-99A NXjlTHY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD1{Nz61OVgzKM7:TR?= NYnrZphGW0GQR1XS
NTERA-S-cl-D1 M2OzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjaTWM2OD1{Nz63Nlk6KM7:TR?= M4DPS3NCVkeHUh?=
PANC-10-05 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYft[HRGUUN3ME2yO{44Pzd3IN88US=> M{TTVHNCVkeHUh?=
NCI-H2405 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDWU|dKSzVyPUK3Mlk{QDdizszN NEHs[nNUSU6JRWK=
MDA-MB-415 M4DGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPEdWRoUUN3ME2yPE41OTN5IN88US=> NEnDblJUSU6JRWK=
NCI-H2342 M{TuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDv[HI3UUN3ME2yPE42OjhzIN88US=> NV[wRo1oW0GQR1XS
TGBC24TKB NWfie5M5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHGe254UUN3ME2yPE44OTF5IN88US=> NFLVTolUSU6JRWK=
LU-134-A NHXTOFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHofVFsUUN3ME2yPE46OjZzIN88US=> MUXTRW5ITVJ?
SCC-4 M{DLTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWDXfppZUUN3ME2zNU4xPDl2IN88US=> NUO1O|B5W0GQR1XS
Saos-2 NIj6VXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{fLVGlEPTB;M{GuPVMxPiEQvF2= MmXSV2FPT0WU
RERF-LC-MS MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzVTWM2OD1|Mj64NlMyKM7:TR?= M4jHcnNCVkeHUh?=
M14 NFj3NGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\0TWM2OD1|Mj65O|Y1KM7:TR?= M{nUNHNCVkeHUh?=
HPAF-II MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[zZ5NIUUN3ME2zN{42ODFzIN88US=> M3TwSnNCVkeHUh?=
NCI-H1755 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWj5PJh{UUN3ME2zOE4{OzB3IN88US=> MXHTRW5ITVJ?
D-392MG MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDNcmJKSzVyPUO1Mlg3PzRizszN NV6zboZEW0GQR1XS
A704 NW\DfJZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEW0NItKSzVyPUO2MlA1OjdizszN NV7CPGhoW0GQR1XS
CP50-MEL-B NEnONm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1WxXGlEPTB;M{[uNVkyOSEQvF2= NWH6NZNkW0GQR1XS
EW-18 M4\Xb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDaTWM2OD1|Nj60OVIh|ryP MU\TRW5ITVJ?
WM-115 NUfiT|VQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\SUYlKSzVyPUO2MlgxQTlizszN MX\TRW5ITVJ?
LU-65 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDmNHJuUUN3ME2zO{4yPDF5IN88US=> M4WwT3NCVkeHUh?=
NCI-H1563 NH\pR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjsRoNKSzVyPUO3MlI1QDRizszN MWDTRW5ITVJ?
DBTRG-05MG NX7yWW52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF35dZlKSzVyPUO4MlA3QTFizszN MWTTRW5ITVJ?
NCI-H630 NHrzXIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPwTWM2OD1|OD60O|E1KM7:TR?= NW\oT|RxW0GQR1XS
NCI-H1155 M4fHNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:0VY5KSzVyPUO5MlI1OiEQvF2= MnzzV2FPT0WU
OVACR-3 MljmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYO0d|JzUUN3ME2zPU46OTl3IN88US=> MkH0V2FPT0WU
OAW-42 NH7jOVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1GyeWlEPTB;NECuOFI2QCEQvF2= MYrTRW5ITVJ?
JVM-2 NIPNN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoqxTWM2OD12MT6yOFE2KM7:TR?= M2rPN3NCVkeHUh?=
C3A MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7ye4JKSzVyPUSxMlM1PDdizszN M1W4OXNCVkeHUh?=
HT55 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LnfWlEPTB;NEKuNlg1OSEQvF2= M3LxNnNCVkeHUh?=
OVCAR-4 NH\CPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{nBUmlEPTB;NEKuNlk4PCEQvF2= MkTyV2FPT0WU
MEG-01 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4G0T2lEPTB;NEKuOFYyPiEQvF2= M4TINHNCVkeHUh?=
NCI-H82 M2\jfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrOTWM2OD12Mz65PFkzKM7:TR?= MWXTRW5ITVJ?
JEG-3 NH\QUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{Lzb2lEPTB;NESuPVQ4KM7:TR?= M2f6UnNCVkeHUh?=
BPH-1 MoD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm2cGpKSzVyPUS2MlM6QThizszN MXfTRW5ITVJ?
MPP-89 NVewSHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;sVWVUUUN3ME20O{4zQDl6IN88US=> NIHl[ZZUSU6JRWK=
ALL-PO M4\GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjNTWM2OD12Nz60NVg5KM7:TR?= MnPFV2FPT0WU
HT MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzUTWM2OD12Nz60PVIh|ryP M1vIfXNCVkeHUh?=
NCI-H2347 NH3MbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmC4TWM2OD12OD6wO|E2KM7:TR?= MYLTRW5ITVJ?
A2780 M4X1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTR7LkSyNlgh|ryP Mn;OV2FPT0WU
KARPAS-299 M3LQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XNd2lEPTB;NEmuOVEyQSEQvF2= MYPTRW5ITVJ?
NCI-H1651 NIPDZ3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmL1TWM2OD12OT64PFIyKM7:TR?= MkjnV2FPT0WU

... Click to View More Cell Line Experimental Data
In vivo PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

Protocol

Kinase Assay:

[1]
+ Expand

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
Cell Research:

[1]
+ Expand
  • Cell lines: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • Concentrations: 0.01-1 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (Only for Reference)
Animal Research:

[1]
+ Expand
  • Animal Models: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • Formulation: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • Dosages: 0-150 mg/kg
  • Administration: Given by gavage
    (Only for Reference)

Solubility (25°C)

In vitro Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing. 		6 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 483.99
Formula

C24H29N7O2.HCl
CAS No. 827022-32-2
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03472573 Recruiting Recurrent B Acute Lymphoblastic Leukemia|Refractory B Acute Lymphoblastic Leukemia Sidney Kimmel Cancer Center at Thomas Jefferson University|Pfizer|Thomas Jefferson University May 9 2018 Phase 1
NCT03423199 Recruiting Breast Neoplasms National Cancer Center Japan|Pfizer|Korean Cancer Study Group February 9 2018 Phase 3
NCT03147287 Recruiting Metastatic Breast Cancer Dana-Farber Cancer Institute|Pfizer August 9 2017 Phase 2
NCT02905318 Recruiting Prostate Cancer Canadian Cancer Trials Group|Pfizer February 9 2017 Phase 2
NCT03535506 Recruiting DCIS Georgetown University|Pfizer October 8 2018 Phase 2
NCT03609047 Not yet recruiting Breast Cancer Stage II|Breast Cancer Stage III European Organisation for Research and Treatment of Cancer - EORTC|Pfizer January 7 2019 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

CDK Signaling Pathway Map

CDK Inhibitors with Unique Features

  • Pan CDK Inhibitor

    BAY 1000394 : Pan-CDK1/2/3/4/7/9 inhibitor, IC50=5-25 nM.

  • Most Potent CDK Inhibitor

    LY2835219 : CDK4, IC50=2 nM; CDK6, IC50=10 nM.

  • CDK Inhibitor in Clinical Trial

    Dinaciclib (SCH727965) : Phase III for Chronic Lymphocytic Leukemia (CLL).

  • Newest CDK Inhibitor

    NU6027 : Potent ATR/CDK inhibitor, inhibits CDK1/2, ATR and DNA-PK with Ki of 2.5 μM/1.3 μM, 0.4 μM and 2.2 μM, enter cells more readily than the 6-aminopurine-based inhibitors.

Related CDK Products

  • SU9516 New

    SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.

  • Ro-3306 New

    RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with Ki of 20 nM, >15-fold selectivity against a diverse panel of human kinases.

  • Purvalanol A New

    Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively.

  • Palbociclib (PD0332991) Isethionate

    Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

    Features:The 1st specific inhibitor for CDK4/6 to show promise in multiple cancers.

  • Dinaciclib (SCH727965)

    Dinaciclib (SCH727965) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Phase 3.

  • Flavopiridol HCl

    Flavopiridol HCl competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Phase 1/2.

  • Roscovitine (Seliciclib,CYC202)

    Roscovitine (Seliciclib, CYC202) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.

  • abemaciclib mesylate (LY2835219)

    abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.

  • Ribociclib (LEE011)

    Ribociclib (LEE011) is an orally available, and highly specific CDK4/6 inhibitor. Phase 3.

  • SNS-032 (BMS-387032)

    SNS-032 (BMS-387032) has firstly been described as a selective inhibitor of CDK2 with IC50 of 48 nM in cell-free assays and is 10- and 20-fold selective over CDK1/CDK4. It is also found to be sensitive to CDK7/9 with IC50 of 62 nM/4 nM, with little effect on CDK6. Phase 1.

Tags: buy Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl supplier | purchase Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl cost | Palbociclib (PD-0332991) HCl manufacturer | order Palbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID